A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

被引：38
|
作者：
Chari, Ajai
Berdeja, Jesus G.
Oriol, Albert
van de Donk, Niels W. C. J.
Rodriguez, Paula
Askari, Elham
Mateos, Maria-Victoria
Minnema, Monique C.
Verona, Raluca
Girgis, Suzette
Prior, Thomas
Hilder, Brandi W.
Russell, Jeffery
Goldberg, Jenna D.
Krishnan, Amrita
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133873
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma
    Pillarisetti, Kodandaram
    Edavettal, Suzanne
    Mendona, Mark
    Li, Yingzhe
    Tornetta, Mark
    Babich, Alexander
    Majewski, Nate
    Husovsky, Matt
    Reeves, Dara
    Walsh, Eileen
    Chin, Diana
    Luistro, Leopoldo
    Joseph, Jocelin
    Chu, Gerald
    Packman, Kathryn
    Shetty, Shoba
    Elsayed, Yusri
    Attar, Ricardo
    Gaudet, Francois
    BLOOD, 2020, 135 (15) : 1232 - 1243
  • [22] The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
    Hammons, Lindsay
    Szabo, Aniko
    Janardan, Abhishek
    Bhatlapenumarthi, Vineel
    Annyapu, Evanka
    Dhakal, Binod
    Al Hadidi, Samer
    Radhakrishnan, Sabarinath Venniyil
    Narra, Ravi
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Janz, Siegfried
    Zangari, Maurizio
    Lentzsch, Suzanne
    van Rhee, Frits
    Crescencio, Juan Carlos Rico
    D'Souza, Anita
    Chakraborty, Rajshekhar
    Mohan, Meera
    Schinke, Carolina
    HAEMATOLOGICA, 2024, 109 (03) : 906 - 914
  • [23] Pivotal Phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed/Refractory Multiple Myeloma (RRMM)
    Schinke, C.
    Touzeau, C.
    Minnema, M. C.
    van de Donk, N. W.
    Rodriguez-Otero, P.
    Mateos, M. -V.
    Rasche, L.
    Ye, J. C.
    Vishwamitra, D.
    Ma, X.
    Qin, X.
    Campagna, M.
    Masterson, T.
    Hilder, B.
    Tolbert, J.
    Renaud, T.
    Goldberg, J.
    Heuck, C.
    Chari, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 82 - 83
  • [24] Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
    Schinke, Carolina D.
    Touzeau, Cyrille
    Minnema, Monique C.
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Rasche, Leo
    Ye, Jing Christine
    Vishwamitra, Deeksha
    Ma, Xuewen
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara J.
    Hilder, Brandi
    Tolbert, Jaszianne A.
    Renaud, Thomas
    Goldberg, Jenna
    Heuck, Christoph
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Magen, Hila
    Morillo, Daniel
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle
    Beelen, Melissa
    Vanak, Jill
    Banerjee, Arnob
    Cohen, Yael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S50
  • [26] Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab
    Lery, Marion
    Perrot, Aurore
    Ortiz-Brugues, Ariadna
    Vigarios, Emmanuelle
    Anghel, Diana
    Bories, Pierre
    Sibaud, Vincent
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (02) : 376 - 377
  • [27] Phase I Trial of MCARH109, a First-in-Class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T-cell Therapy for Relapsed or Refractory Multiple Myeloma: Updated Analysis
    Jurgens, Eric
    Firestone, Ross
    Chaudhari, Jagrutiben
    Hosszu, Kinga
    Devlin, Sean
    Shah, Urvi
    Landa, Jonathan
    McAvoy, Devin
    Lesokhin, Alexander
    Korde, Neha
    Hassoun, Hani
    Tan, Carlyn
    Hultcrantz, Malin
    Shah, Gunjan
    Landau, Heather
    Chung, David
    Scordo, Michael
    Dogan, Ahmet
    Giralt, Sergio
    Riviere, Isabelle
    Brentjens, Renier
    Smith, Eric
    Wang, Xiuyan
    Usmani, Saad
    Mailankody, Sham
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S62 - S63
  • [28] Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D
    Bräuner-Osborne, H
    Jensen, AA
    Sheppard, PO
    Brodin, B
    Krogsgaard-Larsen, P
    O'Hara, P
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2001, 1518 (03): : 237 - 248
  • [29] An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study
    Qin, Ling
    Zhong, Yuping
    Huang, Dongping
    Xie, Haitang
    Du, Xin
    Liao, Aijun
    Zhang, Hongli
    Cai, Shengli
    Lu, Jin
    BLOOD, 2024, 144 : 4736 - 4737
  • [30] Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
    Jurgens, Eric M.
    Firestone, Ross S.
    Chaudhari, Jagrutiben
    Hosszu, Kinga
    Devlin, Sean M.
    Shah, Urvi A.
    Landa, Jonathan
    Mcavoy, Devin P.
    Lesokhin, Alexander M.
    Korde, Neha
    Hassoun, Hani
    Tan, Carlyn R.
    Hultcrantz, Malin
    Shah, Gunjan L.
    Landau, Heather J.
    Chung, David J.
    Scordo, Michael
    Eren, Ozgur Can
    Dogan, Ahmet
    Giralt, Sergio A.
    Park, Jae H.
    Riviere, Isabelle
    Brentjens, Renier J.
    Smith, Eric L.
    Wang, Xiuyan
    Usmani, Saad Z.
    Mailankody, Sham
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (05) : 498 - 504
12345